Refractory (Relapsed) Neuroblastoma Treatment

MIBG patient
Children's Now Offers
MIBG Therapy in a
Special Treatment Room

For children fighting high-risk, recurrent or refractory neuroblastoma or pheochromocytoma, the options for treatment oftentimes become limited, as do the number of facilities capable of providing some form of treatment. 

We are now offering MIBG therapy. We are one of only a handful of centers in the country to offer this advanced treatment.

What is I-131 MIBG Treatment?

I-131 MIBG is a treatment that uses radio-labeled iodine molecules (I-131) attached to a compound called metaiodobenzylguanidine (MIBG). 

I-131 MIBG specifically targets tumors like neuroblastoma and pheochromocytoma. It is taken up by these tumors and delivers a higher dose of radiation directly to the tumor while preserving normal adjacent tissue. 

MIBG therapy is:

  • One of the most effective treatments for children with relapsed neuroblastoma
  • Shown to typically have fewer side effects than traditional chemotherapy and radiation therapy
  • A treatment that often provides a better quality of life for these patients

Video: Behind-the-Scenes Look at MIBG

Behind-the-Scenes Look at MIBGView

Follow a young patient and his family as they receive MIBG therapy at the Aflac Cancer Center. 


Our team of neuroblastoma experts oversees the treatment of all children with refractory neuroblastoma or pheochromocytoma who come to the Aflac Cancer Center. Each one of our patients is assigned to a specific physician who knows the child and family's unique clinical and social needs.

In addition to the pediatric oncologists and radiologists listed below, the refractory neuroblastoma treatment group includes nurses, a child life specialist and a social worker specializing in neuroblastoma patients.

Kelly Goldsmith, M.D. Director, Recurrent/Refractory Neuroblastoma Program
Pediatric Hematology/Oncology
  John Bradley Wyly, M.D.

Pediatric Radiologist

Adina Alazraki, M.D., F.A.A.P.

Pediatric Radiologist


About Our Specialized Facility

MIBG patient roomAfter a child receives MIBG treatment, he is radioactive for about four-to-seven days. He must stay in a special room and minimize contact with parents and siblings, and avoid contact with other patients.

We understand how important it is for parents to be close to their child while he is in the hospital. That is why we specially designed a separate room where parents can stay that is adjacent to the child’s room. 

The two rooms are equipped with a closed-circuit TV system that allows the child and his parents to stay connected at all times. Families can see, talk, watch movies and play video games together via our specialized close-circuit TV system. 

A parent can still go in to the patient’s room, but this unique parent-room set up helps decrease radiation exposure to the family.

Additional features of our MIBG facility includes:

  • Lead lined walls to prevent unnecessary exposure to radiation
  • Clear shields to protect family members, doctors and nurses from the radiation while still being able to see the child
  • Paper and plastic coverings on all walls, flooring and other surfaces

Clinical Trials

In addition to MIBG treatment, the Aflac Cancer Center offers patients access to approximately 250 clinical trials, including some of the most novel treatment options in the country. Visit our clinical trial page for more information.